1. Home
  2. News & Events
  3. Newsroom

Newsroom

2021

“The IMI model aligns with our way of working”

28/05/2021
TB Alliance is one of IMI's Associated Partners. Ana Maria Harkins, its Director of External Affairs, says that the partnership with IMI allows them to expand funding beyond a small and mostly static group of donors
Image by Mary Long via Shutterstock

“The scale of the funding enables real impact”

17/05/2021
The Children's Tumor Foundation is one of IMI's Associated Partners. Annette Bakker, the Foundation's president, says that the unique IMI model ensures alignment between industry and public partners.
Image by alphaspirit.it via Shutterstock

IMI impact event series – registration open!

30/04/2021
Today, IMI is globally recognised as a pioneer of open innovation and an attractive model for successful PPPs in research. A true partnering machine, we forge collaborations that bring together stakeholders including universities, large pharmaceutical companies, SMEs, patient groups, and medicine regulators, as well as companies in other health-related sectors, such as diagnostics, imaging, and IT. In this context we have decided to showcase IMI’s impact in specific areas, starting...
Impact knob hand_shutterstock_by Olivier Le Moal

Focus on: pain

29/04/2021
In April, we focussed on IMI projects in the field of pain research.
Image by AePatt Journey via Shutterstock

IMI impact on diabetes

29/04/2021
IMI has a strong diabetes project portfolio, with several projects addressing different aspects of the disease. Some are studying the underlying causes of the disease and the internal processes that lead to the destruction of the cells in the pancreas that produce insulin. Others aim to detect clues as to how the disease will progress in different patients. Finally, many projects focus on detecting, preventing and treating the complications associated with diabetes.
Diabetes young caucasian man with a blue circle shutterstock by nito.jpg

IMI impact on data

29/04/2021
IMI has had ‘big data’ projects since its creation. Projects are putting ‘big data’ principles into practice to advance research in the fields of cardiovascular disease, haematological malignancies (blood cancers), Alzheimer’s disease, and prostate cancer. IMI also boasts a number of projects working on health-related mobile and digital technologies.
data finger

IMI impact on dementia

29/04/2021
IMI has over 20 projects in this area accounting for around 10 % of IMI’s budget. Most focus on Alzheimer’s disease and other forms of dementia, but we also have projects on Parkinson’s disease, pain, and multiple sclerosis, for example. The projects cover the whole spectrum of medical research and drug development, and patients play an active role in many projects, bringing their knowledge and experience of their disease to the table.
Alzheimer_red string_shutterstock by By LightField Studios

Focus on: rare diseases

03/03/2021
Science has tended to neglect diseases that affect small numbers of people, but that is changing.
Image by Serhii Hrebeniuk via Shutterstock

Focus on: coronavirus

29/01/2021
In March 2020, IMI responded rapidly to the emerging global COVID-19 pandemic. 144 applications led to 8 projects, and the funding pot was increased from €45 million to €72 million. Read about the projects and communications activities surrounding the Call.
social distance greeting

2020

Season's greetings

18/12/2020
We wish all of our stakeholders a relaxing, peaceful holiday season and a happy, healthy new year. The IMI Programme Office is closed from 24 December to 3 January inclusive.
IMI greetings card 2020 with the text 'Happy New Year'

Focus on: technology convergence

30/11/2020
IMI can provide a transparent, neutral and, importantly, pre-competitive setting that can provide regulators with solid evidence that new technologies are reliable. The technology will move very quickly, so we should, too.
heart data points by Illus_man Shutterstock

Quality and quantity – IMI projects’ scientific publications

23/11/2020
IMI’s projects are prolific in their production of scientific papers, and what’s more, they’re delivering quality and quantity. Much scientific knowledge is shared via scientific papers that are reviewed by other scientists and published in journals. Every year, IMI analyses the publications produced by IMI projects. The latest report, prepared by Clarivate, studies IMI project publications up until the end of 2019. It shows that IMI projects continue to deliver...

Focus on: SMEs

30/10/2020
In October we focussed on the ways IMI boosts the competitiveness of SMEs.

Major IMI patient education project embarks on new chapter

21/10/2020
IMI patient education project EUPATI has set up an independent, non-profit foundation to build on the project’s work. The creation of the EUPATI Foundation secures the project’s legacy and paves the way for the further development of patient education resources in Europe and beyond.
EUPATI has developed educational materials. Image credit Pixabay / StartupStockPhotos

UPDATED: Meet the IMI projects already helping to fight COVID-19

16/10/2020
A number of IMI’s projects are making valuable contributions to the global effort to tackle COVID-19. The contributions include knowledge, tools and expertise, and while some come from projects in the infectious disease field, projects working in other areas, such as data management and Alzheimer’s disease, are also stepping up to the plate.
Particles of the SARS-CoV-2 virus, which causes COVID-19. Credit: National Institute of Allergy and Infectious Diseases, NIH

Focus on: FAIRified data

15/09/2020
When it comes to big data, no other industry has as much at stake as the biopharmaceutical sector. Data from sources like health records, imaging, genome sequencing and wearables are potentially very valuable, and could drive massive improvements in European health systems. Making this data FAIR (findable, accessible, interoperable and reusable) is a simple message with wide appeal to researchers who spend an inordinate amount of time finding, processing, organising...

SARS… or something else?

20/08/2020
RAPID-COVID’s platform can detect up to 30 different infections in one test. This will help stem the spread of COVID-19 by getting the diagnosis right - especially important in flu season
swab

Two IMI projects to work with EMA on COVID-19

30/07/2020
The EHDEN and ConcePTION projects plus the ADVANCE/VAC4EU will help the European Medicines Agency (EMA) gather real world data on COVID-19 vaccines and treatments once they are approved and being used in day-to-day clinical practice.
The SARS-C0V-2 virus, which causes COVID-19. Image: NIAID

ECSEL JU launches Call for proposals on decentralised clinical trials

10/06/2020
ECSEL JU, the joint undertaking for electronic components and systems, has launched a Call for proposals on decentralised clinical trials that would complement the work of IMI’s Trials@Home project. IMI and ECSEL JU have been sharing information on their projects, and exploring ways to deepen their collaboration, for a number of years. Now, that collaboration is set to deepen with the launch of an ECSEL JU Call for proposals that...
Mobile devices. Image by Dariusz Sankowski from Pixabay

IMI2 – Calls 22 and 23: updated topics available and webinar registration open

25/05/2020
Tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, clinical trial data, and patient adherence are the topics proposed for IMI’s next Calls for proposals. IMI has published updated versions of the draft texts of the topics that are slated for inclusion in IMI’s next Calls for proposals, IMI2 – Calls 22 and 23, which are scheduled for launch on 23 June 2020. In addition, registration is...

The story so FAIR

13/05/2020
Making data FAIR could supercharge medicine development. FAIRplus is putting the principles into practice.
analytics

8 new COVID-19 projects announced

12/05/2020
The Innovative Medicines Initiative has provisionally selected 8 projects for funding from its fast-track Call for proposals on coronavirus diagnostics and treatments. In addition, it has boosted the IMI funding pot from EUR 45 million to EUR 72 million. On top of this, EFPIA companies, IMI Associated Partners and other organisations will contribute over EUR 45 million to the projects.
sars-cov2

When data is FAIR, citizens ultimately reap the benefit

04/05/2020
Generated at ever-increasing speed and potentially extremely valuable, big data could drive massive improvements in European health systems, but only if we can agree on a set of rules for the use, reuse and management.
robot

Socio-economic legacy: EHR4CR's data reuse revolution

30/04/2020
Electronic health record (EHR) systems are widely used in Europe and worldwide. These rich data sources can be used to address bottle necks in clinical trial design and, crucially, patient recruitment. However the lack of interoperability between EHR systems has traditionally limited the ability to efficiently combine the data across large populations for research analysis. The EHR4CR project was launched in 2011 to develop a platform that can use de-identified...
data by pexels

Addressing the impacts of COVID-19 on IMI Calls and projects

08/04/2020
At the IMI Programme Office, we are very conscious of the fact that the COVID-19 outbreak poses significant challenges for IMI projects and applicants alike. Here we summarise the steps taken at IMI to mitigate the situation, and provide links to resources that may be helpful. Information for applicants We have extended the following Call deadlines: IMI2 – Call 18 (stage 2): deadline extended to 2 April 2020 IMI2 –...

Draft future Call topics published online

06/04/2020
Tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, clinical trial data, and patient adherence are the topics proposed for IMI’s next Calls for proposals.
Close up of a hand holding a tiny lightbulb. Credit: Shutterstock

New tools and trials combat the resurgence of whooping cough

30/03/2020
EU-funded researchers hope a greater understanding of interactions between pertussis bacteria and the immune system, together with a toolkit for testing new vaccines, will help prevent whooping cough disease and deaths in babies worldwide.
Pertussis bacteria

COVID-19 is a sign of the times

10/03/2020
Repurposing existing drugs could get us out of the current predicament but it’s clear we need to prepare for more pandemics
Novel coronavirus

The secret life of tumours

26/02/2020
In recent funding calls, IMI has turned its attention to emerging cancer therapies, seeking better understanding of things like the effect of tumour microenvironment on immunotherapy success
Human colon cancer cells

CANCER-ID hunts for cancer clues in blood samples

20/02/2020
Today, many cancer patients have to undergo biopsy surgery to provide doctors with the cell samples they need to diagnose the disease and monitor how well a treatment is working. IMI’s CANCER-ID project has paved the way for the use of ‘liquid biopsies’ drawn from a blood sample.
Blood samples

IMI planning EUR 45 million Call for proposals on COVID-19

17/02/2020
The fast-track, single stage Call will cover therapeutics and diagnostics to tackle the outbreak of the novel coronavirus. IMI plans to launch a Call for proposals on COVID-19, the novel coronavirus that was first reported in China in December 2019 and has since infected over 71 000 people and killed 1 700. The Call, which will be launched in early March, focuses on the development of: therapeutics to address the...

Focus on: patient involvement

09/01/2020
Patients and drug developers look at an illness from entirely different perspectives. Closing this perspective gap is one of the unmet social needs that drove the creation of IMI. Though the industry agreed for a long time that patient engagement was welcome and necessary, nobody really knew how to go about it. There was one concern that worried them in particular: will people with no training in medicine R&D be...

2019

PET scans that show brain changes caused by Alzheimer’s give doctors confidence in diagnosis

20/12/2019
Being able to visualise the pathology linked to the disease is a big benefit for diagnosis and patient management. Researchers from an IMI project that set out to get definitive data on the role of amyloid PET scans in Alzheimer’s disease diagnosis are hearing from physicians that being able to visualise the underlying pathology linked to the disease is a big benefit for diagnosis and patient management. The ability to...
PET

Sign up for the IMI2 – Call 20 webinars

17/12/2019
IMI2 – Call 20 will be launched in January 2020 and features topics on cancer, tuberculosis, psoriasis, drugs based on proteins, and vaccines. Registration is now open for the IMI2 - Call 20 webinars, which will be held from 22 to 31 January 2020 inclusive. Registration is free but obligatory via the webinar page. There are webinars on all Call topics as well as IMI's rules and procedures and opportunities...

Focus on: Alzheimer's disease

06/12/2019
Alzheimer’s is a scientific failure. It's an area of research suited to a public private partnership because it offers companies a chance to pool the lessons they've learned, mistakes they've made, and data they've compiled from years of unsuccessful attempts to develop treatments. The Alzheimer's research we fund is looking at the underlying biology rather than going after late-stage cures. We know now that there has been too much focus...

Why it’s so hard to make new antibiotics

15/11/2019
There’s no lack of chemicals that can kill bacteria. One of the main reasons there have been so few new antibiotics developed in recent decades – apart from a poor return on investment – is that researchers have run out of ideas on how to outwit the protective mechanisms of Gram-negative bacteria.
Petri

For small companies, IMI projects can help tap into new markets

11/11/2019
CEO of TRISTAN project partner tells IMI about the opportunities that can open up as a result of getting involved in an IMI project. Karin von Wachenfeldt, Ph. D. is the CEO of Truly Labs, a Swedish SME that carries out preclinical research. Tell us about your company: Truly Labs is a small preclinical CRO (contract research organisation) that provides lab services for drug development. We are based in Lund...

Focus: Antimicrobial resistance 

04/11/2019
Antimicrobial resistance is becoming one of the defining problems of our time. As bacteria become resistant to the drugs that are supposed to kill them, scientists, policy makers and the pharma industry are looking at different ways to fix the problem before it’s too late. IMI has invested heavily in AMR research. To date, we have invested almost €800 million on 14 projects. In November, we will be taking a...

New IMI project puts immune cells in the spotlight

04/11/2019
EUR 27 million Immune-Image project will advance the use of imaging technologies to track immune cells. Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The 5-year Immune-Image project, which started recently, aims to pioneer the...

Trial of second Ebola vaccine to start in Democratic Republic of the Congo

31/10/2019
The trial of the two-dose Ebola vaccine regimen aims to help tackle the current outbreak and strengthen future Ebola epidemic preparedness. An international consortium will soon start a large-scale clinical trial of an Ebola vaccine regimen in the Democratic Republic of the Congo (DRC), which is currently experiencing the second worst Ebola epidemic in history. IMI has contributed significantly to the development of the two-dose vaccine regimen, which is manufactured by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Meet IMI at BIO-Europe 2019

29/10/2019
In two weeks’ time, IMI will be in Hamburg for BIO-Europe 2019, which runs from 11 to 13 November. A highlight for IMI will be a session on the morning of 12 November on EU support for small and medium-sized enterprises (SMEs). Among the speakers is IMI’s Magali Poinot, who will explain the benefits for SMEs of participating in IMI projects and show how SMEs can get involved in IMI...

Spotlight on early-career investigators: an interview with Benjamin Falcon

23/10/2019
Benjamin Falcon is a scientist in the IMPRiND project, which is investigating the role of misfolded proteins in Alzheimer’s and Parkinson’s diseases. Dr Benjamin Falcon is a postdoctoral scientist at the UK Medical Research Council Laboratory of Molecular Biology, working to untangle the mysteries of neurodegenerative conditions such as Alzheimer’s disease. He completed his PhD with Professor Michel Goedert and has developed an impressive track record of findings that progress...

Good data on medication safety for new and expectant mothers is overdue

18/10/2019
A survey intends to get a clear picture of women’s experiences of medicating while pregnant or breast-feeding Video: Caroline Swain was five weeks pregnant when she was diagnosed with breast cancer. Her health providers didn't initially know what treatments she could take. © The Pregnancy and Medicines Initiative The problem Evidence suggests that up to 95% of the five million women who get pregnant in the EU every year will...

Find out about IMI’s future funding opportunities

15/10/2019
Cancer, tuberculosis, and psoriasis are among the topics that could be part of our next Call for proposals, IMI2 – Call 20. Also slated for inclusion in the Call are topics on drugs based on proteins, and vaccines.

How do you prepare for a pandemic?

10/10/2019
IMI Director Pierre Meulien talks about IMI's reaction to the biggest Ebola outbreak in history and how the world is better prepared for future major epidemics.

Focus on: Ebola

03/10/2019
During the month of October we will be taking a look at some of the results of our Ebola-related research projects.